Invesaro

Stocks Health care DXR

NASDAQ · Health care

Daxor Corp (DXR)

Daxor Corp reported revenue of $1.4M in fiscal 2011, down 8.4% from a year earlier. It posted a net loss of $7.2M. In fiscal 2011 capital spending exceeded operating cash flow by $6.6M. At December 31, 2011 it held $59.6K in cash.

Free, no password. An email when DXR files with the SEC.

Price
$8.72
+3.56% on the day · November 9, 2026
52-week range $8.40 to $14.76
Market cap
$50.9M
Revenue (FY2011)
$1.4M
-8.4% year on year
Net margin
-496.8%

Key facts about Daxor Corp

Net worth
Daxor Corp has a market value (market cap) of $50.9M at the latest share price, and shareholders' equity of $36.2M on its balance sheet at December 31, 2011. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Revenue and profit
In fiscal 2011 revenue was $1.4M (-8.4% year on year), with a net loss of $7.2M.
Cash flow
In fiscal 2011 operations used $6.5M of cash.
Dividend
Daxor Corp paid dividends of $0.25 per share in fiscal 2011.

What Daxor Corp does

Its shares trade on NASDAQ under the ticker DXR.

Revenue and profit by year

Revenue
FY11: $1.6M $1.6M FY11FY11: $1.4M $1.4M FY11
Net income
FY11: $5M $5M FY11FY11: -$7.2M -$7.2M FY11

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2011$1.4M-$5.8M-$7.2M-$1.70-$6.6M
2011$1.6M-$5.7M$5M$1.17-$6M

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Dividends

Daxor Corp paid $0.25 per share in fiscal 2011. It paid out $1.1M in cash dividends.

Fiscal yearPer sharePaid outOf profit
2011$0.25$1.1Mn/a
2011$1.00$4.2M85%

Per share as declared (or paid, where only that is reported), adjusted for stock splits the company itself restated. Yield is the latest fiscal year's dividend over the current price.

Latest SEC filings

What Daxor Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 24, 2026
  2. September 4, 2026
  3. August 31, 2026
  4. August 31, 2026
  5. August 31, 2026
  6. June 24, 2026
  7. June 17, 2026
  8. June 3, 2026
  9. June 2, 2026
  10. May 21, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 1, 2026. Insider transactions on SEC

Insider trades

What the people running Daxor Corp did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider bought or sold shares on the open market in the last 90 days. The 1 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days
DateInsiderWhatSharesPriceValueFiling
August 28, 2026 Jefferies JohnChief Medical Officer Received as pay 2,451 - - Form 4
June 23, 2026 Feldschuh Jonathan AdamChief Scientific Officer, Director Received as pay 25,000 - - Form 4
June 23, 2026 Feldschuh Michael RichardChief Executive Officer, Director Received as pay 30,000 - - Form 4
June 23, 2026 Michel Robert JChief Financial Officer Received as pay 12,000 - - Form 4
April 8, 2026 Feldschuh Michael RichardChief Executive Officer, Director Bought 1,000 $9.07 $9.1K Form 4
March 31, 2026 Michel Robert JChief Financial Officer Bought 1,000 $9.90 $9.9K Form 4
March 20, 2026 Jefferies JohnChief Medical Officer Bought 3,656 - - Form 4
March 20, 2026 Jefferies JohnChief Medical Officer Bought 2,285 - - Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns DXR

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

No holder of 5% or more has filed about this company in that window.

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

4 insiders reported holding 381,660 shares in total, about $3.3M at the last price.

HolderSharesAs of
Feldschuh Michael RichardChief Executive Officer, Director 243,694 June 23, 2026
Feldschuh Jonathan AdamChief Scientific Officer, Director 78,908 June 23, 2026
Michel Robert JChief Financial Officer 33,050 June 23, 2026
Jefferies JohnChief Medical Officer 26,008 August 28, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about DXR

What does Daxor Corp do?

Daxor Corp is a company in the Health care sector, listed on NASDAQ as DXR. Its shares trade on NASDAQ under the ticker DXR.

What is Daxor Corp's net worth?

Daxor Corp has a market value (market cap) of $50.9M at the latest share price, and shareholders' equity of $36.2M on its balance sheet at December 31, 2011. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Daxor Corp profitable?

No. In fiscal 2011 it reported a net loss of $7.2M on revenue of $1.4M.

How much revenue does Daxor Corp make?

In fiscal 2011 Daxor Corp reported revenue of $1.4M. That is 8.4% less than a year earlier.

When did Daxor Corp last report?

Its newest filing of any kind is the form N-CEN/A filing from September 24, 2026.

Does Daxor Corp pay a dividend?

Yes. Daxor Corp paid dividends of $0.25 per share in fiscal 2011.

Similar companies

Compare DXR with

Compare DXR with any company

Follow DXR

Get an email when Daxor Corp files with the SEC: results, executive changes, material agreements and annual reports.

Free, no password. An email when DXR files with the SEC.

Where the numbers come from

Financial figures are the values Daxor Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.